Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 32 entries
Sorted by: Best Match Show Resources per page
Special issue on II Translational Meeting from the Spanish Melanoma Group.

Annals of translational medicine

Gonzalez-Cao M, Algarra SM.
PMID: 29114541
Ann Transl Med. 2017 Oct;5(19):383. doi: 10.21037/atm.2017.09.18.

No abstract available.

Cite
Gonzalez-Cao M, Algarra SM. Special issue on II Translational Meeting from the Spanish Melanoma Group. Ann Transl Med. 2017;5(19):383doi: 10.21037/atm.2017.09.18.
Gonzalez-Cao, M., Algarra, S. M. (2017). Special issue on II Translational Meeting from the Spanish Melanoma Group. Annals of translational medicine, 5(19), 383. https://doi.org/10.21037/atm.2017.09.18
Gonzalez-Cao, Maria, et al. "Special issue on II Translational Meeting from the Spanish Melanoma Group." Annals of translational medicine vol. 5,19 (2017): 383. doi: https://doi.org/10.21037/atm.2017.09.18
Gonzalez-Cao M, Algarra SM. Special issue on II Translational Meeting from the Spanish Melanoma Group. Ann Transl Med. 2017 Oct;5(19):383. doi: 10.21037/atm.2017.09.18. PMID: 29114541; PMCID: PMC5653510.
Copy Download .nbib Format: NLM
Up-Down Reader: An Open Source Program for Efficiently Processing 50% von Frey Thresholds.

Frontiers in pharmacology

Gonzalez-Cano R, Boivin B, Bullock D, Cornelissen L, Andrews N, Costigan M.
PMID: 29765323
Front Pharmacol. 2018 May 01;9:433. doi: 10.3389/fphar.2018.00433. eCollection 2018.

Most pathological pain conditions in patients and rodent pain models result in marked alterations in mechanosensation and the gold standard way to measure this is by use of von Frey fibers. These graded monofilaments are used to gauge the...

Cite
Gonzalez-Cano R, Boivin B, Bullock D, et al. Up-Down Reader: An Open Source Program for Efficiently Processing 50% von Frey Thresholds. Front Pharmacol. 2018;9:433doi: 10.3389/fphar.2018.00433.
Gonzalez-Cano, R., Boivin, B., Bullock, D., Cornelissen, L., Andrews, N., & Costigan, M. (2018). Up-Down Reader: An Open Source Program for Efficiently Processing 50% von Frey Thresholds. Frontiers in pharmacology, 9433. https://doi.org/10.3389/fphar.2018.00433
Gonzalez-Cano, Rafael, et al. "Up-Down Reader: An Open Source Program for Efficiently Processing 50% von Frey Thresholds." Frontiers in pharmacology vol. 9 (2018): 433. doi: https://doi.org/10.3389/fphar.2018.00433
Gonzalez-Cano R, Boivin B, Bullock D, Cornelissen L, Andrews N, Costigan M. Up-Down Reader: An Open Source Program for Efficiently Processing 50% von Frey Thresholds. Front Pharmacol. 2018 May 01;9:433. doi: 10.3389/fphar.2018.00433. eCollection 2018. PMID: 29765323; PMCID: PMC5938897.
Copy Download .nbib Format: NLM
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.

Therapeutic advances in medical oncology

Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, Teixido C, Molina-Vila MA, Viteri S, De Los Llanos Gil M, Algarra SM, Perez-Ruiz E, Marquez-Rodas I, Rodriguez-Abreu D, Blanco R, Puertolas T, Royo MA, Rosell R.
PMID: 29383037
Ther Adv Med Oncol. 2018 Jan 18;10:1758834017749748. doi: 10.1177/1758834017749748. eCollection 2018.

BACKGROUND: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated METHODS: Total RNA from 17 NSCLC and 21 melanoma patients was analyzed by quantitative reverse transcription PCR. STAT3 and Rantes, YAP1 and CXCL5, DNMT1,...

Cite
Karachaliou N, Gonzalez-Cao M, Crespo G, et al. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther Adv Med Oncol. 2018;10:1758834017749748doi: 10.1177/1758834017749748.
Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., Algarra, S. M., Perez-Ruiz, E., Marquez-Rodas, I., Rodriguez-Abreu, D., Blanco, R., Puertolas, T., Royo, M. A., & Rosell, R. (2018). Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic advances in medical oncology, 101758834017749748. https://doi.org/10.1177/1758834017749748
Karachaliou, Niki, et al. "Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients." Therapeutic advances in medical oncology vol. 10 (2018): 1758834017749748. doi: https://doi.org/10.1177/1758834017749748
Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, Teixido C, Molina-Vila MA, Viteri S, De Los Llanos Gil M, Algarra SM, Perez-Ruiz E, Marquez-Rodas I, Rodriguez-Abreu D, Blanco R, Puertolas T, Royo MA, Rosell R. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther Adv Med Oncol. 2018 Jan 18;10:1758834017749748. doi: 10.1177/1758834017749748. eCollection 2018. PMID: 29383037; PMCID: PMC5784541.
Copy Download .nbib Format: NLM
Reversible Axonal Dystrophy by Calcium Modulation in Frataxin-Deficient Sensory Neurons of YG8R Mice.

Frontiers in molecular neuroscience

Mollá B, Muñoz-Lasso DC, Riveiro F, Bolinches-Amorós A, Pallardó FV, Fernandez-Vilata A, de la Iglesia-Vaya M, Palau F, Gonzalez-Cabo P.
PMID: 28912677
Front Mol Neurosci. 2017 Aug 30;10:264. doi: 10.3389/fnmol.2017.00264. eCollection 2017.

Friedreich's ataxia (FRDA) is a peripheral neuropathy involving a loss of proprioceptive sensory neurons. Studies of biopsies from patients suggest that axonal dysfunction precedes the death of proprioceptive neurons in a dying-back process. We observed that the deficiency of...

Cite
Mollá B, Muñoz-Lasso DC, Riveiro F, et al. Reversible Axonal Dystrophy by Calcium Modulation in Frataxin-Deficient Sensory Neurons of YG8R Mice. Front Mol Neurosci. 2017;10:264doi: 10.3389/fnmol.2017.00264.
Mollá, B., Muñoz-Lasso, D. C., Riveiro, F., Bolinches-Amorós, A., Pallardó, F. V., Fernandez-Vilata, A., de la Iglesia-Vaya, M., Palau, F., & Gonzalez-Cabo, P. (2017). Reversible Axonal Dystrophy by Calcium Modulation in Frataxin-Deficient Sensory Neurons of YG8R Mice. Frontiers in molecular neuroscience, 10264. https://doi.org/10.3389/fnmol.2017.00264
Mollá, Belén, et al. "Reversible Axonal Dystrophy by Calcium Modulation in Frataxin-Deficient Sensory Neurons of YG8R Mice." Frontiers in molecular neuroscience vol. 10 (2017): 264. doi: https://doi.org/10.3389/fnmol.2017.00264
Mollá B, Muñoz-Lasso DC, Riveiro F, Bolinches-Amorós A, Pallardó FV, Fernandez-Vilata A, de la Iglesia-Vaya M, Palau F, Gonzalez-Cabo P. Reversible Axonal Dystrophy by Calcium Modulation in Frataxin-Deficient Sensory Neurons of YG8R Mice. Front Mol Neurosci. 2017 Aug 30;10:264. doi: 10.3389/fnmol.2017.00264. eCollection 2017. PMID: 28912677; PMCID: PMC5583981.
Copy Download .nbib Format: NLM
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.

Nature communications

Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, Arance A, Muñoz-Couselo E, Espinosa E, Puertolas T, Diaz Beveridge R, Ochenduszko S, Villanueva MJ, Basterretxea L, Bellido L, Rodriguez D, Campos B, Montagut C, Drozdowskyj A, Molina MA, Lopez-Martin JA, Berrocal A.
PMID: 34853302
Nat Commun. 2021 Dec 01;12(1):7008. doi: 10.1038/s41467-021-26572-6.

Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance....

Cite
Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, et al. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nat Commun. 2021;12(1):7008doi: 10.1038/s41467-021-26572-6.
Gonzalez-Cao, M., Mayo de Las Casas, C., Oramas, J., Berciano-Guerrero, M. A., de la Cruz, L., Cerezuela, P., Arance, A., Muñoz-Couselo, E., Espinosa, E., Puertolas, T., Diaz Beveridge, R., Ochenduszko, S., Villanueva, M. J., Basterretxea, L., Bellido, L., Rodriguez, D., Campos, B., Montagut, C., Drozdowskyj, A., Molina, M. A., Lopez-Martin, J. A., & Berrocal, A. (2021). Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nature communications, 12(1), 7008. https://doi.org/10.1038/s41467-021-26572-6
Gonzalez-Cao, Maria, et al. "Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial." Nature communications vol. 12,1 (2021): 7008. doi: https://doi.org/10.1038/s41467-021-26572-6
Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, Arance A, Muñoz-Couselo E, Espinosa E, Puertolas T, Diaz Beveridge R, Ochenduszko S, Villanueva MJ, Basterretxea L, Bellido L, Rodriguez D, Campos B, Montagut C, Drozdowskyj A, Molina MA, Lopez-Martin JA, Berrocal A. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nat Commun. 2021 Dec 01;12(1):7008. doi: 10.1038/s41467-021-26572-6. PMID: 34853302.
Copy Download .nbib Format: NLM
Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich's Ataxia.

Antioxidants (Basel, Switzerland)

Seco-Cervera M, González-Cabo P, Pallardó FV, Romá-Mateo C, García-Giménez JL.
PMID: 33321938
Antioxidants (Basel). 2020 Dec 10;9(12). doi: 10.3390/antiox9121257.

The thioredoxin family consists of a small group of redox proteins present in all organisms and composed of thioredoxins (TRXs), glutaredoxins (GLRXs) and peroxiredoxins (PRDXs) which are found in the extracellular fluid, the cytoplasm, the mitochondria and in the...

Cite
Seco-Cervera M, González-Cabo P, Pallardó FV, et al. Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich's Ataxia. Antioxidants (Basel). 2020;9(12)doi: 10.3390/antiox9121257.
Seco-Cervera, M., González-Cabo, P., Pallardó, F. V., Romá-Mateo, C., & García-Giménez, J. L. (2020). Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich's Ataxia. Antioxidants (Basel, Switzerland), 9(12), . https://doi.org/10.3390/antiox9121257
Seco-Cervera, Marta, et al. "Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich's Ataxia." Antioxidants (Basel, Switzerland) vol. 9,12 (2020). doi: https://doi.org/10.3390/antiox9121257
Seco-Cervera M, González-Cabo P, Pallardó FV, Romá-Mateo C, García-Giménez JL. Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich's Ataxia. Antioxidants (Basel). 2020 Dec 10;9(12). doi: 10.3390/antiox9121257. PMID: 33321938; PMCID: PMC7763308.
Copy Download .nbib Format: NLM
The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.

Cell reports

Walter J, Bolognin S, Poovathingal SK, Magni S, Gérard D, Antony PMA, Nickels SL, Salamanca L, Berger E, Smits LM, Grzyb K, Perfeito R, Hoel F, Qing X, Ohnmacht J, Bertacchi M, Jarazo J, Ignac T, Monzel AS, Gonzalez-Cano L, Krüger R, Sauter T, Studer M, de Almeida LP, Tronstad KJ, Sinkkonen L, Skupin A, Schwamborn JC.
PMID: 34686322
Cell Rep. 2021 Oct 19;37(3):109864. doi: 10.1016/j.celrep.2021.109864.

Increasing evidence suggests that neurodevelopmental alterations might contribute to increase the susceptibility to develop neurodegenerative diseases. We investigate the occurrence of developmental abnormalities in dopaminergic neurons in a model of Parkinson's disease (PD). We monitor the differentiation of human...

Cite
Walter J, Bolognin S, Poovathingal SK, et al. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1. Cell Rep. 2021;37(3):109864doi: 10.1016/j.celrep.2021.109864.
Walter, J., Bolognin, S., Poovathingal, S. K., Magni, S., Gérard, D., Antony, P. M. A., Nickels, S. L., Salamanca, L., Berger, E., Smits, L. M., Grzyb, K., Perfeito, R., Hoel, F., Qing, X., Ohnmacht, J., Bertacchi, M., Jarazo, J., Ignac, T., Monzel, A. S., Gonzalez-Cano, L., Krüger, R., Sauter, T., Studer, M., de Almeida, L. P., Tronstad, K. J., Sinkkonen, L., Skupin, A., & Schwamborn, J. C. (2021). The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1. Cell reports, 37(3), 109864. https://doi.org/10.1016/j.celrep.2021.109864
Walter, Jonas, et al. "The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1." Cell reports vol. 37,3 (2021): 109864. doi: https://doi.org/10.1016/j.celrep.2021.109864
Walter J, Bolognin S, Poovathingal SK, Magni S, Gérard D, Antony PMA, Nickels SL, Salamanca L, Berger E, Smits LM, Grzyb K, Perfeito R, Hoel F, Qing X, Ohnmacht J, Bertacchi M, Jarazo J, Ignac T, Monzel AS, Gonzalez-Cano L, Krüger R, Sauter T, Studer M, de Almeida LP, Tronstad KJ, Sinkkonen L, Skupin A, Schwamborn JC. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1. Cell Rep. 2021 Oct 19;37(3):109864. doi: 10.1016/j.celrep.2021.109864. PMID: 34686322.
Copy Download .nbib Format: NLM
Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer-Reply.

JAMA oncology

Gonzalez-Cao M, Martinez-Picado J, Rosell R.
PMID: 32910172
JAMA Oncol. 2020 Nov 01;6(11):1810-1811. doi: 10.1001/jamaoncol.2020.3400.

No abstract available.

Cite
Gonzalez-Cao M, Martinez-Picado J, Rosell R. Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer-Reply. JAMA Oncol. 2020;6(11):1810-1811doi: 10.1001/jamaoncol.2020.3400.
Gonzalez-Cao, M., Martinez-Picado, J., & Rosell, R. (2020). Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer-Reply. JAMA oncology, 6(11), 1810-1811. https://doi.org/10.1001/jamaoncol.2020.3400
Gonzalez-Cao, Maria, et al. "Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer-Reply." JAMA oncology vol. 6,11 (2020): 1810-1811. doi: https://doi.org/10.1001/jamaoncol.2020.3400
Gonzalez-Cao M, Martinez-Picado J, Rosell R. Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer-Reply. JAMA Oncol. 2020 Nov 01;6(11):1810-1811. doi: 10.1001/jamaoncol.2020.3400. PMID: 32910172.
Copy Download .nbib Format: NLM
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.

Nature communications

Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, Arance A, Muñoz-Couselo E, Espinosa E, Puertolas T, Diaz Beveridge R, Ochenduszko S, Villanueva MJ, Basterretxea L, Bellido L, Rodriguez D, Campos B, Montagut C, Drozdowskyj A, Molina MA, Lopez-Martin JA, Berrocal A.
PMID: 34853302
Nat Commun. 2021 Dec 01;12(1):7008. doi: 10.1038/s41467-021-26572-6.

Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance....

Cite
Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, et al. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nat Commun. 2021;12(1):7008doi: 10.1038/s41467-021-26572-6.
Gonzalez-Cao, M., Mayo de Las Casas, C., Oramas, J., Berciano-Guerrero, M. A., de la Cruz, L., Cerezuela, P., Arance, A., Muñoz-Couselo, E., Espinosa, E., Puertolas, T., Diaz Beveridge, R., Ochenduszko, S., Villanueva, M. J., Basterretxea, L., Bellido, L., Rodriguez, D., Campos, B., Montagut, C., Drozdowskyj, A., Molina, M. A., Lopez-Martin, J. A., & Berrocal, A. (2021). Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nature communications, 12(1), 7008. https://doi.org/10.1038/s41467-021-26572-6
Gonzalez-Cao, Maria, et al. "Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial." Nature communications vol. 12,1 (2021): 7008. doi: https://doi.org/10.1038/s41467-021-26572-6
Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, Arance A, Muñoz-Couselo E, Espinosa E, Puertolas T, Diaz Beveridge R, Ochenduszko S, Villanueva MJ, Basterretxea L, Bellido L, Rodriguez D, Campos B, Montagut C, Drozdowskyj A, Molina MA, Lopez-Martin JA, Berrocal A. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nat Commun. 2021 Dec 01;12(1):7008. doi: 10.1038/s41467-021-26572-6. PMID: 34853302; PMCID: PMC8636498.
Copy Download .nbib Format: NLM
Liquid biopsy for lung cancer early detection.

Journal of thoracic disease

Santarpia M, Liguori A, D'Aveni A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, Lazzari C, Altavilla G, Rosell R.
PMID: 29780635
J Thorac Dis. 2018 Apr;10:S882-S897. doi: 10.21037/jtd.2018.03.81.

Molecularly targeted therapies and immune checkpoint inhibitors have markedly improved the therapeutic management of advanced lung cancer. However, it still remains the leading cause of cancer-related mortality worldwide, with disease stage at diagnosis representing the main prognostic factor. Detection...

Cite
Santarpia M, Liguori A, D'Aveni A, et al. Liquid biopsy for lung cancer early detection. J Thorac Dis. 2018;10:S882-S897doi: 10.21037/jtd.2018.03.81.
Santarpia, M., Liguori, A., D'Aveni, A., Karachaliou, N., Gonzalez-Cao, M., Daffinà, M. G., Lazzari, C., Altavilla, G., & Rosell, R. (2018). Liquid biopsy for lung cancer early detection. Journal of thoracic disease, 10S882-S897. https://doi.org/10.21037/jtd.2018.03.81
Santarpia, Mariacarmela, et al. "Liquid biopsy for lung cancer early detection." Journal of thoracic disease vol. 10 (2018): S882-S897. doi: https://doi.org/10.21037/jtd.2018.03.81
Santarpia M, Liguori A, D'Aveni A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, Lazzari C, Altavilla G, Rosell R. Liquid biopsy for lung cancer early detection. J Thorac Dis. 2018 Apr;10:S882-S897. doi: 10.21037/jtd.2018.03.81. PMID: 29780635; PMCID: PMC5945693.
Copy Download .nbib Format: NLM
Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM).

Annals of translational medicine

Espinosa E, Márquez-Rodas I, Soria A, Berrocal A, Manzano JL, Gonzalez-Cao M, Martin-Algarra S.
PMID: 29114547
Ann Transl Med. 2017 Oct;5(19):389. doi: 10.21037/atm.2017.08.10.

Immunotherapy has become a key element in the treatment of several tumors, such as lung carcinoma and melanoma. Immunotherapy, unlike classical chemotherapy and targeted drugs, may yield long-term survival, even in patients who stop treatment due to toxicity. This...

Cite
Espinosa E, Márquez-Rodas I, Soria A, et al. Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM). Ann Transl Med. 2017;5(19):389doi: 10.21037/atm.2017.08.10.
Espinosa, E., Márquez-Rodas, I., Soria, A., Berrocal, A., Manzano, J. L., Gonzalez-Cao, M., Martin-Algarra, S. (2017). Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM). Annals of translational medicine, 5(19), 389. https://doi.org/10.21037/atm.2017.08.10
Espinosa, Enrique, et al. "Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM)." Annals of translational medicine vol. 5,19 (2017): 389. doi: https://doi.org/10.21037/atm.2017.08.10
Espinosa E, Márquez-Rodas I, Soria A, Berrocal A, Manzano JL, Gonzalez-Cao M, Martin-Algarra S. Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM). Ann Transl Med. 2017 Oct;5(19):389. doi: 10.21037/atm.2017.08.10. PMID: 29114547; PMCID: PMC5653511.
Copy Download .nbib Format: NLM
Mitochondrial dysfunction induced by frataxin deficiency is associated with cellular senescence and abnormal calcium metabolism.

Frontiers in cellular neuroscience

Bolinches-Amorós A, Mollá B, Pla-Martín D, Palau F, González-Cabo P.
PMID: 24860428
Front Cell Neurosci. 2014 May 13;8:124. doi: 10.3389/fncel.2014.00124. eCollection 2014.

Friedreich ataxia is considered a neurodegenerative disorder involving both the peripheral and central nervous systems. Dorsal root ganglia (DRG) are the major target tissue structures. This neuropathy is caused by mutations in the FXN gene that encodes frataxin. Here,...

Cite
Bolinches-Amorós A, Mollá B, Pla-Martín D, et al. Mitochondrial dysfunction induced by frataxin deficiency is associated with cellular senescence and abnormal calcium metabolism. Front Cell Neurosci. 2014;8:124doi: 10.3389/fncel.2014.00124.
Bolinches-Amorós, A., Mollá, B., Pla-Martín, D., Palau, F., & González-Cabo, P. (2014). Mitochondrial dysfunction induced by frataxin deficiency is associated with cellular senescence and abnormal calcium metabolism. Frontiers in cellular neuroscience, 8124. https://doi.org/10.3389/fncel.2014.00124
Bolinches-Amorós, Arantxa, et al. "Mitochondrial dysfunction induced by frataxin deficiency is associated with cellular senescence and abnormal calcium metabolism." Frontiers in cellular neuroscience vol. 8 (2014): 124. doi: https://doi.org/10.3389/fncel.2014.00124
Bolinches-Amorós A, Mollá B, Pla-Martín D, Palau F, González-Cabo P. Mitochondrial dysfunction induced by frataxin deficiency is associated with cellular senescence and abnormal calcium metabolism. Front Cell Neurosci. 2014 May 13;8:124. doi: 10.3389/fncel.2014.00124. eCollection 2014. PMID: 24860428; PMCID: PMC4026758.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 32 entries